Robak, Tadeusz, Kazmierczak, Maciej, Jarque, Isidro, Musteata, Vasile, Trelinski, Jacek, Cooper, Nichola, Kiessling, Peter, Massow, Ute, Woltering, Franz, Snipes, Rose, Ke, Juan, Langdon, Grant, Bussel, James B. and Jolles, Stephen
2020.
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Blood Advances
4
(17)
, pp. 4136-4146.
10.1182/bloodadvances.2020002003
|
![[thumbnail of Robak-2020-Phase--multiple-dose-study-of-an-fc.pdf]](https://orca.cardiff.ac.uk/style/images/fileicons/application_pdf.png "Robak-2020-Phase--multiple-dose-study-of-an-fc.pdf") |
PDF
- Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (0B) |
Official URL: http://dx.doi.org/10.1182/bloodadvances.2020002003
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine |
| Additional Information: | PDF added in accordance with the publisher's policies at http://v2.sherpa.ac.uk/id/publication/32010 (accesses 7/9/20)// |
| Publisher: | American Society of Hematology |
| ISSN: | 2473-9529 |
| Funders: | N/A |
| Date of First Compliant Deposit: | 7 September 2020 |
| Date of Acceptance: | 15 July 2020 |
| Last Modified: | 16 Sep 2021 11:00 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/134675 |
Citation Data
Cited 63 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric